Medtronic Receives 'CE' Mark for Sentrant Introducer Sheath, Complementing Market-Leading Aortic Stent Grafts

Thu Apr 4, 2013 8:00am EDT

* Reuters is not responsible for the content in this press release.

For best results when printing this announcement, please click on the link below:

Distinguishing Features of New Accessory for Endovascular Interventions Include Optimal Seal for
Superior Hemostasis and Reinforced Coil for Proven Kink Resistance

MINNEAPOLIS-- April 4, 2013 -- Complementing its market-leading portfolio of stent grafts for the
endovascular repair of aortic aneurysms and related conditions, Medtronic, Inc. (NYSE: MDT)
announced today that the Sentrant Introducer Sheath has received the CE (Conformité Européenne)
mark and will soon be launched internationally. 

The Sentrant Introducer Sheath is designed for use with Medtronic's Endurant II AAA and Valiant
Captivia Stent Graft Systems, the market-leading devices in their product categories worldwide,
and can also be used with similar devices for endovascular repair. Inserted at the access site in
the patient's femoral artery, the tapered tube is advanced up into the iliac arteries to
facilitate the implant procedure, enabling smooth passage of the stent graft delivery system and
accessory devices en route to the treatment site in the aorta.

Distinguishing features of the Sentrant Introducer Sheath include:

*Optimal seal compared to competitive sheaths for superior hemostasis during the procedure.
*Reinforced coil for proven kink resistance.
*Hydrophilic coating and flexibility for easy tracking through tortuous and calcified iliacs.
*Radiopaque marker band for clear visibility.
*Dilator locking mechanism for secure positioning.

To accommodate a range of anatomies, the Sentrant Introducer Sheath is made in diameters of 12-26
French and lengths of 28cm and 64cm. Compatible with the Archer Super Stiff Guidewire and the
Reliant Stent Graft Balloon Catheter, it expands Medtronic's accessories toolkit for endovascular
aortic interventions.

Medtronic's complete portfolio of stent grafts and related accessories will be on display during
the Charing Cross symposium in London from April 6-9. 

In collaboration with leading clinicians, researchers and scientists worldwide, Medtronic offers
the broadest range of innovative medical technology for the interventional and surgical treatment
of cardiovascular disease and cardiac arrhythmias. The company strives to offer products and
services that deliver clinical and economic value to healthcare consumers and providers around the

Medtronic, Inc. ( ), headquartered in Minneapolis, is
the global leader in medical technology -- alleviating pain, restoring health and extending life
for millions of people around the world. 

Any forward-looking statements are subject to risks and uncertainties such as those described in
Medtronic's periodic reports on file with the Securities and Exchange Commission. Actual results
may differ materially from anticipated results.

- end -


Joseph McGrath
Public Relations

Jeff Warren
Investor Relations


This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients.

The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the
information contained therein.

Source: Medtronic, Inc. via Thomson Reuters ONE


Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.